并发RB1和TP53改变定义了一组具有组织学转化风险且临床结局较差的EGFR突变肺癌亚群
本研究基于2014至2018年二代测序数据,比较EGFR/RB1/TP53三突变肺癌与无RB1和TP53改变的转移性EGFR突变肺癌。三突变患者占EGFR突变肺癌的5%(43/863),组织学转化风险为18%(7/39),无基线TP53和RB1改变者无转化。三突变患者至EGFR-TKI停药时间更短,全基因组加倍和AID/APOBEC突变特征富集。
要点
- EGFR/RB1/TP53三突变肺癌占EGFR突变肺癌的5%(43/863),组织学转化风险为18%(7/39)。
- 三突变患者至EGFR-TKI停药时间较EGFR/TP53突变和仅EGFR突变者更短(9.5 vs 12.3 vs 36.6个月,p=2×10⁻⁹)。
- 三突变肺癌全基因组加倍发生率高于一般NSCLC和SCLC(80% vs 34%,p<5×10⁻⁹;vs 51%,p<0.002)。
核心结论
- EGFR/TP53/RB1突变肺癌具有独特的组织学转化风险,25%表现为原发SCLC或最终小细胞转化。
- 三突变肺癌富集全基因组加倍和AID/APOBEC超突变,可能代表谱系可塑性的早期基因组决定因素。
研究设计与样本
- 研究纳入2014至2018年经二代测序鉴定的EGFR/RB1/TP53突变肺癌患者,与未治疗、无RB1和TP53改变的转移性EGFR突变肺癌患者进行比较。
- 评估指标包括至EGFR-酪氨酸激酶抑制剂停药时间、总生存、SCLC转化率和基因组改变。
主要发现
- EGFR/RB1/TP53突变肺癌占EGFR突变肺癌的5%(43/863),组织学转化风险为18%(7/39),而无基线TP53和RB1改变的EGFR突变肺癌无转化。
- 无论是否发生转化,EGFR/TP53/RB1突变肺癌患者至停药时间短于EGFR/TP53突变和仅EGFR突变患者(9.5 vs 12.3 vs 36.6个月,p=2×10⁻⁹)。
- 三突变人群全基因组加倍发生率高于一般NSCLC和SCLC(80% vs 34%,p<5×10⁻⁹;vs 51%,p<0.002)。
- 三突变癌症中最终小细胞组织学者的全基因组加倍进一步富集(7/7转化前加4/4基线SCLC vs 23/32从未转化,p=0.05)。
- 发生转化的三突变肺癌富集活化诱导胞苷脱氨酶/载脂蛋白B mRNA编辑酶催化多肽样突变特征(错误发现率=0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: EGFR-mutant lung cancers are clinically and genomically heterogeneous with concurrent RB transcriptional corepressor 1 (RB1)/tumor protein p53 (TP53) alterations identifying a subset at increased risk for small cell transformation. The genomic alterations that induce lineage plasticity are unknown. METHODS: Patients with EGFR/RB1/TP53-mutant lung cancers, identified by next-generation sequencing from 2014 to 2018, were compared to patients with untreated, metastatic EGFR-mutant lung cancers without both RB1 and TP53 alterations. Time to EGFR-tyrosine kinase inhibitor discontinuation, overall survival, SCLC transformation rate, and genomic alterations were evaluated. RESULTS: Patients with EGFR/RB1/TP53-mutant lung cancers represented 5% (43 of 863) of EGFR-mutant lung cancers but were uniquely at risk for transformation (7 of 39, 18%), with no transformations in EGFR-mutant lung cancers without baseline TP53 and RB1 alterations. Irrespective of transformation, patients with EGFR/TP53/RB1-mutant lung cancers had a shorter time to discontinuation than EGFR/TP53- and EGFR-mutant -only cancers (9.5 versus 12.3 versus 36.6 months, respectively, p = 2 × 10-9). The triple-mutant population had a higher incidence of whole-genome doubling compared to NSCLC and SCLC at large (80% versus 34%, p < 5 × 10-9 versus 51%, p < 0.002, respectively) and further enrichment in triple-mutant cancers with eventual small cell histology (seven of seven pre-transformed plus four of four baseline SCLC versus 23 of 32 never transformed, respectively, p = 0.05). Activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like mutation signature was also enriched in triple-mutant lung cancers that transformed (false discovery rate = 0.03). CONCLUSIONS: EGFR/TP53/RB1-mutant lung cancers are at unique risk of histologic transformation, with 25% presenting with de novo SCLC or eventual small cell transformation. Triple-mutant lung cancers are enriched in whole-genome doubling and Activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like hypermutation which may represent early genomic determinants of lineage plasticity.
引用
- Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. J Thorac Oncol. 2019. PMID: 31228622. doi:10.1016/j.jtho.2019.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。